You are here: Home » Companies » News
Business Standard

Strides doubles provision to Rs 1,300 crore on Mylan dispute

Strides is evaluating each claim made by Mylan, and says it can successfully defend them

BS Reporter  |  Bengaluru 

Strides doubles provision to Rs 1,300 cr on Mylan dispute

Pharma major Strides Shasun Ltd has doubled its outlay for potential compensation of $200 million (Rs 1,300 crore) after US Pharma major Mylan, which bought the Indian firm's unit Agila Specialities in 2013, raised red flag over regulatory concerns over its factories and the deal agreement. Strides also said it is evaluating each claim made by Mylan.

Mylan bought Agila Specialities, a drug firm with factories in Karnataka for $1.75 billion in 2013. This is one of the major pharmaceutical deals in the country. In August, the US Food and Drug Administration (USFDA) had warned Mylan of not complying with current good manufacturing practice (CGMP) in three factories, including two that it bought from Strides.

Strides, earlier known as Strides Arcolab, had initially deposited $100 million for potential damages in an escrow account, which it has increased to $200 million. It accounts for provisions for potential claims under the sales and purchase agreements in relation to certain regulatory concerns, Badree Komandur, chief financial officer and company secretary, said in a notification to the Bombay Stock Exchange on Tuesday.

"The company believes it can successfully defend these claims and is in the process of evaluating each claim notified by Mylan," Komandur said, adding that claims, if honoured, would not exceed the amount that has been provisioned. Strides did not disclose the charges.

Strides stock on the Bombay Stock Exchange closed 0.03 per cent or Re 0.35 up at Rs 1,278.35 on trading on Tuesday.

The USFDA in August had questioned Mylan's corporate quality system to achieve compliance of CGMP on these facilities that had recurrent violations such as not following written procedures that are designed to prevent microbiological contamination of drug products that need to be sterile.

"If there is a liability, it will be around 10 per cent of the total deal value. The shareholders would have an impact of that amount," said Shriram Subramanian, founder and managing director of InGovern Research Services. "Strides got a high premium for the Agila deal."

Mylan had valued the deal at $1.65 billion, holding $ 100 million for potential fines by regulators.

First Published: Wed, December 16 2015. 00:23 IST
RECOMMENDED FOR YOU